Sleep Disturbance Among HIV-Infected and Uninfected Veterans
To the Editors: Although sleep disturbance has been observed at all stages of HIV infection, [1] [2] [3] [4] the nature of the association between HIV and sleep disturbance has not been rigorously evaluated in the current treatment era. We explored the longitudinal associations between HIV status and self-reported occurrence or severity of sleep disturbance, with adjustment for demographics, comorbidities, and polypharmacy.
We used the Veterans Aging Cohort Study, a longitudinal prospective observational study of HIV-infected and uninfected Veterans enrolled at 8 Veterans Health Administration (VHA) medical centers: Atlanta, Baltimore, Brooklyn and Manhattan, Bronx, Houston, Los Angeles, Pittsburgh, and Washington DC. HIV-infected Veterans were matched one to one with uninfected Veterans by age, race/ethnicity, site of clinical care, and sex. 5 Data for this analysis included electronic health record data and self-report questionnaires completed by participants at enrollment (baseline) (June 2002 through August 2012) and through 6 years of follow-up.
We defined HIV infection as the presence of International Classification of Diseases, Ninth Revision, Clinical Modification, codes for HIV during at least 2 outpatient visits or 1 inpatient event that were confirmed in the immunology case registry of the VHA. 6 Our primary outcomes were sleep disturbance and its severity. Both were assessed on an annual basis using the self-completed HIV Symptom Index 7 over a follow-up period of 6 years. The index elicits the frequency and severity of discomfort for 20 symptoms commonly associated with HIV. If the symptom was present, participants were prompted to indicate the degree of severity, based on a 5-point Likert scale (0 = does not experience the symptom, 1 = experiences the symptom but without bother, 2 = bothered a little by this symptom, 3 = bothered, and 4 = experiences a lot of bother with the symptom).
Sleep disturbance was dichotomized as occurrence (a nonzero response on the Likert scale) or nonoccurrence (a zero response on the Likert scale). Severity was assessed using the ordinal range of responses. Sleep disturbance symptoms were elicited on the survey at baseline and at follow-up visits in years 1-4 and 6, facilitating the longitudinal modeling of sleep disturbance and its severity.
Covariates were selected a priori based on previous sleep disturbance research and data availability. Baseline demographic information included age, sex, and race/ethnicity. All other covariates were updated at each annual assessment. We identified International Classification of Diseases, Ninth Revision, Clinical Modification, codes 1 year before and 6 months after baseline for the following conditions: coronary artery disease, diabetes, liver disease (any of hepatitis B or C, cirrhosis, end-stage liver disease), peripheral vascular disease, renal disease, cerebrovascular disease (including stroke), cancer, heart failure, Chronic obstructive pulmonary disease (COPD), other chronic lung diseases, obstructive sleep apnea, Post-traumatic stress syndrome (PTSD), and drug use or abuse.
Body mass index (BMI; weight in kilograms/height in square meter) and pain (pain level between 0 and 10) were identified using vital sign data. We categorized BMI according to World Health Organization criteria: underweight (BMI , 18.5), normal weight (18.5-24.9), overweight (25-29.9), and obese (BMI $ 30). Smoking status was categorized as current, former, and never smoker. From survey data, we used the Patient Health Questionnaire-2 to assess depressive symptoms. 8 Using the Alcohol Use Disorders Identification Test, [9] [10] [11] we defined hazardous alcohol use as a score of $4 for men and $3 for women. For these time-updated variables, values within 90 days of each survey date were used. If multiple values occurred within this time, the one closest to the survey date was used.
We included a count of unique medications (excluding antiretrovirals) prescribed within 90 days of each survey date over the 6-year follow-up period. Use of selective serotonin reuptake inhibitors (SSRIs), other antidepressants, benzodiazepines, and hazardous opiate use ($120 morphine equivalents per day) were coded as dichotomous indicator variables. Among HIV-infected individuals, we identified use of antiretroviral therapy (ART) within the same time window and a separate marker of efavirenz use, given its historical association with sleep disturbance. 12 CD4 count and HIV RNA were also time updated, and the values closest to survey date were used. Time was quantified as a count variable ranging from 1 to 6 representing the baseline survey and the successive waves of follow-up that we included in the study.
Descriptive characteristics were calculated at baseline: continuous variables with means and SDs or with medians and interquartile ranges (IQR) and dichotomous variables with the percentage of observations. Each characteristic was compared between Veterans with and without HIV infection.
Clinical and demographic characteristics plausibly associated with the presence or severity of sleep disturbance were tested in multivariable longitudinal models that used generalized estimating equations with an autoregressive correlation structure. Approximately 7% of observations were missing. Because we believed the missingness to be at random, 10 imputations of the entire longitudinal dataset were created with a full conditional specification. The associations of clinical and demographic factors with occurrence of sleep disturbance were modeled using logistic regression. We assessed model fit using discrimination (C-statistic) and calibration (Hosmer-Lemeshow x 2 statistic). Severity of sleep disturbance was modeled with a negative binomial distribution. Separate models of each outcome were fit to the combined sample and to the subgroup of HIVinfected individuals. To discern whether the effect of polypharmacy was because of the number of medications taken or of the inclusion of certain classes of medications that might be particularly associated with sleep disturbance, we also included indicators of use of the following medication classes: benzodiazepines, Z-drugs (non-benzodiazepine sleep medications), hazardous opiate use, SSRIs, and other antidepressants. All analyses were performed using SAS version 9.4. Because of the large number of analyses, P values from multivariable models were adjusted for multiple comparisons using the Hochberg method. 13 We included all Veterans Aging Cohort Study participants (N = 7515). The sample was composed predominantly of Black (65%) and nonHispanic (90%) men (95%) of whom 50% were HIV infected. Relative to their uninfected counterparts, HIVinfected individuals were younger (49 6 9 vs 50 6 10 years, P , 0.0001), had a lower BMI (26 6 4 vs 30 6 6 kg/ m 2 , P , 0.0001), were more likely to have liver (54% vs 30%, P , 0.0001) or renal disease (5% vs 3%, P = 0.0003), and less likely to have heart failure (2% vs 3%, P = 0.003), sleep apnea (1% vs 3%, P , 0.0001), PTSD (8% vs 12%, P , 0.0001), drug use/abuse (24% vs 27%, P = 0.006), coronary artery disease (8% vs 12%, P , 0.0001), diabetes (12% vs 22%, P , 0.0001), or peripheral vascular disease (2% vs 3%, P = 0.0002). There were no differences between HIV-infected and uninfected individuals in terms of COPD (5% vs 5%, P = 0.27), other chronic lung conditions (8% vs 9%, P = 0.05), cerebrovascular disease or stroke (0.8% vs 1%, P = 0.05), and cancer (5% vs 5%, P = 0.83). HIVinfected Veterans had lower Alcohol Use Disorders Identification Test C scores [median (IQR): 2 (1-5) vs 3 (1-5), P = 0.001] and fewer prescriptions for benzodiazepines (8% vs 10%, P = 0.003) and other antidepressants (16% vs 18%, P = 0.03). Prescriptions for opiates (HIV infected: 21% vs uninfected: 22%, P = 0.88), SSRIs (19% for both, P = 0.58), and Z-drugs (2% and 3%, respectively, P = 0.79) did not differ by HIV status. Depressive symptom scores were similar in both groups [HIV infected: median 4 (IQR: 1-9) and HIV uninfected: median 3 (IQR 1-5)]. Among HIV-infected Veterans, the mean CD4 count was 410 6 287 cells per cubic millimeter and mean HIV RNA was 37,013 6 170,242 copies per milliliter. Eighty percent were on ART within 90 days of the baseline survey, and 28% were on efavirenz.
Among HIV-infected individuals, 61% experienced sleep disturbance, compared with 58% of uninfected (P = 0.01). The full range of severity scores was observed in both groups, who shared a common median of 2 (bothered a little by this symptom).
In unadjusted models, HIV infection was associated with sleep disturbance [odds ratio (OR) = 1.13; 95% confidence interval (CI): 1.03 to 1.24, P = 0.01] but not its severity (relative risk = 1.03; 95% CI: 0.98 to 1.08, P = 0.32). In multivariable models with adjustment for multiple comparisons, HIV was associated with neither outcome (sleep disturbance-OR: 1.08; 95% CI: 1.01 to 1.15, P = 0.39; severity-relative risk: 1.02; 95% CI: 0.99 to 1.04, P = 0.98).
Variables associated with increased risk of sleep disturbance included (Table 1) depressive symptom score (OR: 3.56; 95% CI: 3.14 to 4.04, P , 0.0001), female sex (1.75; 1.47 to 2.08, P , 0.0001), pain (1.06; 1.03 to 1.08, P = 0.0006), liver disease (1.13; 1.06 to 1.20, P = 0.0068), PTSD (1.81; 1.60 to 2.04, P , 0.0001), hazardous alcohol use (1.15; 1.07 to 1.23, P = 0.0014), current smoking (1.20; 1.10 to 1.30, P = 0.0007), and higher medication count (1.06; 1.05 to 1.08, P , 0.0001). Variables protective against sleep disturbance included age more than 65 years (0.78; 0.69 to 0.87, P = 0.0007), Black race (0.64; 0.60 to 0.69, P , 0.0001), and Hispanic ethnicity (0.76; 0.68 to 0.85, P , 0.0001). When the 5 indicators for specific medication classes were included in the model, only hazardous opiate use was not associated with sleep disturbance. After controlling for these specific medication classes, medication count retained the significance of its association (1.04; 1.03 to 1.06, P = 0.003).
Results for sleep disturbance were similar in the analyses restricted to HIVinfected Veterans. Of note, none of the HIV-specific variables [CD4 count (1.00; 1.00 to 1.00, P = 0.95), HIV RNA (1.00; 1.00 to 1.00, P = 0.90), ART use (1.02; 0.92 to 1.14, P = 0.95), and efavirenz use (0.96; 0.88 to 1.05, P = 0.94)] were associated with occurrence of sleep disturbance.
The C-statistics for the combined and HIV-only samples were 0.78 and 0.77, and both exhibited a good calibration per the Hosmer and Lemeshow goodness-of-fit statistic. 14 The explanatory variables used to model the association between HIV infection and sleep disturbance severity were virtually identical to those used for the dichotomized outcome. Severity was also modeled in combined and HIVinfected-only samples.
STRENGTHS
This longitudinal study explored self-reported sleep disturbance and severity in a large matched cohort of HIV-infected and uninfected Veterans. Adjustment for comorbid conditions and medication counts helped differentiate the relative contributions of chronic disease and polypharmacy. It is notable that the HIV-infected individuals included in this analysis had a high CD4 count at baseline, accurately reflecting the relatively good health of persons comprising the current epidemic.
The question of the generalizability of our results to populations outside of the Veterans Affairs is pertinent. A recent study exploring the overlap between Veterans receiving care in the VHA and civilian cohorts found that VHA enrollees had similar demographic and health characteristics as individuals with Medicaid, Medicare, or private insurance coverage. These results suggest that research done within the VHA may be generalizable to other clinical populations. 15 
LIMITATIONS
The primary limitation of this study was its reliance on a single question from the HIV Symptom Index to assess sleep disturbance. The selfreported outcome essentially reflected degree of severity rather than its true occurrence. Any nonreporting of sleep disturbance might therefore reflect patients' focus on other issues that were of greater concern at that moment. Future studies will include the use of validated sleep questionnaires and physiologic measures of sleep (actigraphy or polysomnography) for a more in-depth understanding of the nature and severity of the sleep disturbance. The dichotomization of the outcome may have decreased our power to detect sleep disturbance, but this limitation is attenuated by the large sample size and the fact that results from the full range of outcome values from the Symptom Index scale did not differ substantively from those of the dichotomized outcome. Although selection bias is always a concern in any observational study, the matching of HIV-infected and uninfected participants by age, race, and gender does address potential imbalance in those important confounders. Lastly, because this study was observational, we make no claims of causality.
CONCLUSIONS
Our results demonstrate that although sleep disturbance is more common among HIV-infected individuals, its higher incidence may be driven by numerous factors known to cause sleep disturbance in the general population, rather than from HIV-specific factors. 
